Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
The efficacy of mometasone/formoterol combination inhaler therapy in children with asthma
EF 2024-25
Résumé
Asthma is the third most common chronic disease in Canada, and is the leading cause of hospitalization in children. Asthma is heterogenous, and although the symptoms that patients experience may be similar, the underlying disease mechanism may be different. It is therefore imperative that we identify novel therapeutic options, and assess their differential impacts on improving asthma symptoms and control.Combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) therapy is currently recommended as first-line treatment for adolescent patients and for symptomatic children with asthma by the Global Initiative for Asthma. However, driven by a lack of evidence in children less than 6 years of age, these recommendations have not yet extended to younger children. These medications may be beneficial in particular subgroups of patients, depending on their underlying disease mechanism. In Canada, mometasone furoate/formoterol, an ICS/LABA medication, is available in a multi-dose inhaler, ideal for pediatric patients, and has been prescribed off-label in pediatric patients less than 12 years of age. However, limited data exists in pediatrics to support its use in improving asthma control and outcomes.We propose a retrospective cohort study, of pediatric patients with asthma, followed in a single-centre asthma clinic, to determine the impact of ICS/LABA therapy on asthma outcomes. The purpose of this study will be to assess the efficacy and safety of mometasone/formoterol therapy in pediatric patients less than 12 years of age with asthma, as compared to conventional ICS therapy, in improving symptom control. Secondary objectives will be to assess predictors of response to ICS/LABA and ICS therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530106
Name
McCoy Jacob
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The efficacy of mometasone/formoterol combination inhaler therapy in children with asthma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Asthma; Children; Combination Therapy; Exacerbations; Inhaler Therapy; Mometasone/Formoterol; Symptom Control
Abstract
Asthma is the third most common chronic disease in Canada, and is the leading cause of hospitalization in children. Asthma is heterogenous, and although the symptoms that patients experience may be similar, the underlying disease mechanism may be different. It is therefore imperative that we identify novel therapeutic options, and assess their differential impacts on improving asthma symptoms and control.Combination inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) therapy is currently recommended as first-line treatment for adolescent patients and for symptomatic children with asthma by the Global Initiative for Asthma. However, driven by a lack of evidence in children less than 6 years of age, these recommendations have not yet extended to younger children. These medications may be beneficial in particular subgroups of patients, depending on their underlying disease mechanism. In Canada, mometasone furoate/formoterol, an ICS/LABA medication, is available in a multi-dose inhaler, ideal for pediatric patients, and has been prescribed off-label in pediatric patients less than 12 years of age. However, limited data exists in pediatrics to support its use in improving asthma control and outcomes.We propose a retrospective cohort study, of pediatric patients with asthma, followed in a single-centre asthma clinic, to determine the impact of ICS/LABA therapy on asthma outcomes. The purpose of this study will be to assess the efficacy and safety of mometasone/formoterol therapy in pediatric patients less than 12 years of age with asthma, as compared to conventional ICS therapy, in improving symptom control. Secondary objectives will be to assess predictors of response to ICS/LABA and ICS therapy.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
McCoy, Jacob
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~